Congress Materials - Rheumatology Advanced Practice Providers (RhAPP 2025)
2025 Rheumatology Advanced Practice Providers | Sep 25-27 | Denver, CO
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques Eric Gottenberg, Kathy Sivils, Kim Campbell, Jada Idokogi, Kim Lo, Sophia G. Liva, Elizabeth Adamson, Harman Dhatt, Jonathan J. Hubbard, Ghaith Noaiseh
Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients with Ulcerative Colitis: Results Through Week 24 from the Phase 3 ASTRO Study
Millie Long, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Silke Jörgens, Lingjing Jiang, Hongyan Zhang, Melissa Petrick, Tadakazu Hisamatsu, David T. Rubin, Laurent Peyrin-Biroulet
Guselkumab for Treatment of Juvenile Psoriatic Arthritis: Data Extrapolation from Studies in Adjacent Adult and Pediatric Populations
Herta Crauwels, Sarah Ringold, Samantha Howard, Bart Van Hartingsveldt, Valerie Smith, Meg Jett, Tristan Baguet, Elizabeth Adamson, Soumya D. Chakravarty, Jocelyn H. Leu
Icotrokinra, a Novel Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
Joseph Merola, Philip Mease, Laura Coates, Iain McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shana Hamm, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Daniel Kakaley, Chetan Karyekar, Tasneam Shagroni
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Daniel Kakaley, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Bruce E. Sands, Remo Panaccione, Silvio Danese, Julián Panés, Tadakazu Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, Hewei Li, Melissa Petrick, Mauricio Rosas Ballina, Jessica R. Allegretti, Anita Afzali, David T. Rubin
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
